StockNews.com downgraded shares of Accuray (NASDAQ:ARAY - Free Report) from a buy rating to a hold rating in a research report report published on Saturday morning.
Accuray Stock Performance
Shares of NASDAQ ARAY traded up $0.04 during trading hours on Friday, hitting $1.82. 715,488 shares of the company's stock were exchanged, compared to its average volume of 717,310. The stock has a market capitalization of $187.15 million, a price-to-earnings ratio of -36.40 and a beta of 1.46. The company's 50-day moving average price is $2.06 and its 200-day moving average price is $1.98. The company has a debt-to-equity ratio of 3.51, a current ratio of 1.62 and a quick ratio of 0.88. Accuray has a 1-year low of $1.40 and a 1-year high of $2.95.
Accuray (NASDAQ:ARAY - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.03. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. On average, sell-side analysts expect that Accuray will post 0.01 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Accuray
A number of institutional investors have recently added to or reduced their stakes in ARAY. Thrivent Financial for Lutherans acquired a new stake in shares of Accuray during the 3rd quarter worth approximately $57,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in Accuray by 489.1% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 277,859 shares of the medical equipment provider's stock worth $500,000 after purchasing an additional 230,695 shares during the period. Intech Investment Management LLC acquired a new stake in Accuray during the third quarter worth $41,000. Dynamic Technology Lab Private Ltd bought a new stake in Accuray in the 3rd quarter valued at $231,000. Finally, FMR LLC raised its stake in shares of Accuray by 27.2% in the 3rd quarter. FMR LLC now owns 582,591 shares of the medical equipment provider's stock valued at $1,049,000 after buying an additional 124,459 shares in the last quarter. 64.08% of the stock is owned by institutional investors and hedge funds.
About Accuray
(
Get Free Report)
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Further Reading
Before you consider Accuray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Accuray wasn't on the list.
While Accuray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
